Completed PHASE2 INTERVENTIONAL 3-arm NCT03714594

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

A Randomized Study of the Effects of Dapagliflozin+Saxagliptin in Addition to Metformin Versus Single Addition Saxagliptin or Dapagliflozin on Glucose Metabolism in Patients With DM2 Poorly Controlled With Metformin

Sponsor: University of Pisa

Conditions Type2 Diabetes Mellitus

Interventions Dapagliflozin 10mg Saxagliptin 5mg Saxagliptin 5mg + Dapagliflozin 10 mg

Updated 9 times since 2018 Last updated: Nov 7, 2022 Started: Jul 24, 2018 Primary completion: Aug 31, 2022 Completion: Aug 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Type2 Diabetes Mellitus and is currently completed. University of Pisa leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jun 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Oct 2021 — Jun 2022 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Nov 2019 — Jan 2021 [monthly]

Recruiting PHASE2
Apr 2019 — Nov 2019 [monthly]

Recruiting PHASE2
Nov 2018 — Apr 2019 [monthly]

Recruiting PHASE2

First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Pisa

Data source: University of Pisa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pisa, Italy